Our findings strongly highlight the moonlighting function of GCLM and suggest that a rational combination of P38 MAPK–nuclear GCLM–NF-κB axis inhibition and platinum-based chemotherapy is an efficient approach for the treatment of CRC. Here, MAPK1 is linked to colorectal carcinoma.